Mirum Pharmaceuticals, Inc. MIRM
Deals with insiders in the proxy filed Apr 23, 2026
Proxy, Item 404Deals between MIRM and its directors, executives, owners of more than 5% or their families: a relative on the payroll, a plane the company charters from its CEO, a director's company that buys from it. SEC rules (Item 404) make the company list every such deal over $120,000 in its proxy statement.
New this year
Compared with Apr 14, 2025
Paragraphs about a deal, a person or a relative with nothing like them in the proxy filed Apr 14, 2025.
Transactions with Related Persons and Indemnification“In January 2026, we completed the acquisition of Bluejay Therapeutics, Inc. (“Bluejay”). As consideration for the transaction, we paid an aggregate amount of $224.2 million in cash, net of cash acquired in the transaction, and 4,673,597 shares of our common stock. subject in certain cases to deduction to satisfy applicable taxes, and will pay up to an aggregate of $25.8 million in cash and 522,375 shares of our common stock, subject to certain conditions and deduction to satisfy applicable taxes. Additionally, we are obligated to pay up to an aggregate of $200.0 million upon achievement of certain commercial milestones. Entities affiliated with Frazier Life Sciences IX, L.P. received approximately $26.8 million in cash and 445,975 shares of our common stock, are entitled to receive up to approximately $2.5 million in cash and 49,849 shares of our common stock upon the occurrence of certain conditions, and are entitled to receive their pro rata portion of any payments related to the achievement of the commercial milestones, if and when payable, as consideration in connection with our acquisition of Bluejay.”
Read it in the proxyopen_in_new
Transactions with Related Persons and Indemnification“Immediately following the closing of the acquisition of Bluejay, we completed two private placement offerings pursuant to the two subscription agreements entered into by us with the parties thereto on December 7, 2025 and December 18, 2025 pursuant to which we issued and sold an aggregate of (i) 3,385,149 shares of our common stock at a price per share of $68.48 and (ii) pre-funded warrants (“Pre-Funded Warrants”) to purchase 536,412 shares of our common stock (“Warrant Shares”) at a price per share of $68.4799 per Pre-Funded Warrant, which equals the purchase price per share of our common stock sold in the first private placement, less $0.0001, the exercise price of each Warrant Share, resulting in aggregate gross proceeds of approximately $268.5 million. Entities affiliated with Frazier Life Sciences IX, L.P. purchased 438,588 shares of our common stock and Pre-Funded Warrants to purchase 536,412 shares of our common stock in the first private placement.”
Read it in the proxyopen_in_new
Transactions with Related Persons and Indemnification“Entities affiliated with Frazier Life Sciences IX, L.P. are associated with one of the members of our Board, Mr. Heron, and Frazier Life Sciences IX, L.P. is a beneficial owner of more than 5% of our outstanding capital stock. More information about our relationship with Frazier Life Sciences IX, L.P. can be found in the section titled “Security Ownership of Certain Beneficial Owners and Management. ””
Read it in the proxyopen_in_new
No longer reported 1 paragraph of the proxy filed Apr 14, 2025 with nothing like them this year
Investors’ Rights Agreement“We were party to an Investors’ Rights Agreement (the “Rights Agreement”) with certain holders of our capital stock, including entities affiliated with Frazier as well as certain affiliates of our directors. The Rights Agreement provided such holders with certain registration rights with respect to the registrable securities held by them. The registration rights of each holder terminated July 17, 2024, the fifth anniversary of our initial public offering.”
Read it in last year's proxyopen_in_new
The whole section
As filed
6 paragraphs quoted as filed
Transactions with Related Persons and Indemnification“The following includes a summary of transactions since the beginning of the last fiscal year to which we have been a party in which the amount involved exceeded or will exceed $120,000, and in which any of our directors, director nominees, executive officers or, to our knowledge, beneficial owners of more than 5% of our capital stock or any member of the immediate family of any of the foregoing persons had or will have a direct or indirect material interest, other than equity and other compensation, termination, change in control and other arrangements, which are described under “Executive Compensation. ” We also describe below certain other transactions with our directors, executive officers and stockholders.”
Read it in the proxyopen_in_new
Transactions with Related Persons and Indemnification“In January 2026, we completed the acquisition of Bluejay Therapeutics, Inc. (“Bluejay”). As consideration for the transaction, we paid an aggregate amount of $224.2 million in cash, net of cash acquired in the transaction, and 4,673,597 shares of our common stock. subject in certain cases to deduction to satisfy applicable taxes, and will pay up to an aggregate of $25.8 million in cash and 522,375 shares of our common stock, subject to certain conditions and deduction to satisfy applicable taxes. Additionally, we are obligated to pay up to an aggregate of $200.0 million upon achievement of certain commercial milestones. Entities affiliated with Frazier Life Sciences IX, L.P. received approximately $26.8 million in cash and 445,975 shares of our common stock, are entitled to receive up to approximately $2.5 million in cash and 49,849 shares of our common stock upon the occurrence of certain conditions, and are entitled to receive their pro rata portion of any payments related to the achievement of the commercial milestones, if and when payable, as consideration in connection with our acquisition of Bluejay.”
Read it in the proxyopen_in_new
Transactions with Related Persons and Indemnification“Immediately following the closing of the acquisition of Bluejay, we completed two private placement offerings pursuant to the two subscription agreements entered into by us with the parties thereto on December 7, 2025 and December 18, 2025 pursuant to which we issued and sold an aggregate of (i) 3,385,149 shares of our common stock at a price per share of $68.48 and (ii) pre-funded warrants (“Pre-Funded Warrants”) to purchase 536,412 shares of our common stock (“Warrant Shares”) at a price per share of $68.4799 per Pre-Funded Warrant, which equals the purchase price per share of our common stock sold in the first private placement, less $0.0001, the exercise price of each Warrant Share, resulting in aggregate gross proceeds of approximately $268.5 million. Entities affiliated with Frazier Life Sciences IX, L.P. purchased 438,588 shares of our common stock and Pre-Funded Warrants to purchase 536,412 shares of our common stock in the first private placement.”
Read it in the proxyopen_in_new
Transactions with Related Persons and Indemnification“Entities affiliated with Frazier Life Sciences IX, L.P. are associated with one of the members of our Board, Mr. Heron, and Frazier Life Sciences IX, L.P. is a beneficial owner of more than 5% of our outstanding capital stock. More information about our relationship with Frazier Life Sciences IX, L.P. can be found in the section titled “Security Ownership of Certain Beneficial Owners and Management. ””
Read it in the proxyopen_in_new
Indemnification Agreements“Our amended and restated certificate of incorporation contains provisions limiting the liability of directors, and our amended and restated bylaws provide that we will indemnify each of our directors and officers to the fullest extent permitted under Delaware law. Our amended and restated certificate of incorporation and amended and restated bylaws also provide the Board with discretion to indemnify our employees and other agents when determined appropriate by the Board. In addition, we have entered into an indemnification agreement with each of our directors and executive officers, which will require us to indemnify them.”
Read it in the proxyopen_in_new
Policies and Procedures for Transactions with Related Persons“We maintain a written policy that our executive officers, directors, nominees for election as a director, beneficial owners of more than 5% of any class of our common stock and any members of the immediate family of any of the foregoing persons are not permitted to enter into a related person transaction with us without the approval or ratification of the Board or the Audit Committee. Any request for us to enter into a transaction with an executive officer, director, nominee for election as a director, beneficial owner of more than 5% of any class of our common stock, or any member of the immediate family of any of the foregoing persons, in which the amount involved exceeds $120,000 and such person would have a direct or indirect interest, must be presented to the Board or the Audit Committee for review, consideration and approval or ratification, if applicable. In approving or rejecting any such proposal, the Board or the Audit Committee is to consider the material facts of the transaction, including (a) the risks, costs and benefits to us, (b) the impact on a director’s independence in the event the related person is a director or immediate family member of a director, (c) the terms of the transaction, (d) the availability of other sources for comparable services or products and (e) the terms available to or from, as the case may be, unrelated third parties.”
Read it in the proxyopen_in_new
Paragraphs are compared by their words, not read by AI: one counts as new when no paragraph last year shares half of its words, or when it names a person or company last year's section did not. A deal reported again with a new amount is not new. Always check the filing. Open the proxy ↗ · Last year's proxy ↗
Sources
The related-party section (Item 404) of the latest annual proxy statement (DEF 14A), against last year's, compared by their words.
Also
CEO pay: the same proxy's pay versus performance table.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/MIRM/export.csv") into a cell.